Full Text Journal Articles by
Author John L Marshall

Advertisement

Find full text journal articles






Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.

Mohamed E Salem, J Nicholas Bodor, Alberto Puccini, Joanne Xiu, Richard M Goldberg, Axel Grothey, W Michael Korn, Anthony F Shields, William M Worrilow, Edward S Kim, Heinz-Josef Lenz, John L Marshall, Michael J Hall,

Microsatellite instability-high (MSI-H) and tumor mutational burden (TMB) are predictive biomarkers for immune-checkpoint inhibitors (ICIs). Still, the relationship between the underlying cause(s) of MSI and TMB in tumors remains poorly defined. We investigated associations of TMB to mismatch repair (MMR) protein expression patterns by immunohistochemistry (IHC) and MMR mutations in ... Read more >>

Int. J. Cancer (International journal of cancer)
[2020, :]

Cited: 0 times

View full text PDF listing >>



Molecular profile of BRCA-mutated biliary tract cancers.

Gilbert Spizzo, Alberto Puccini, Joanne Xiu, Richard M Goldberg, Axel Grothey, Anthony F Shields, Sukeshi Patel Arora, Moh'd Khushmann, Mohamed E Salem, Francesca Battaglin, Yasmine Baca, Wafik S El-Deiry, Philip A Philip, Madiha Nassem, Michael Hall, John L Marshall, Florian Kocher, Arno Amann, Dominik Wolf, W Michael Korn, Heinz Lenz, Andreas Seeber,

INTRODUCTION:Prognosis of biliary tract cancers (BTC) remains dismal and novel treatment strategies are needed to improve survival. BRCA mutations are known to occur in BTC but their frequency and the molecular landscape in which they are observed in distinct sites of BTC remain unknown. MATERIAL AND METHODS:Tumour samples from 1292 ... Read more >>

ESMO Open (ESMO open)
[2020, 5(3):]

Cited: 0 times

View full text PDF listing >>



Advertisement

WRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype.

Kai Zimmer, Alberto Puccini, Joanne Xiu, Yasmine Baca, Gilbert Spizzo, Heinz-Josef Lenz, Francesca Battaglin, Richard M Goldberg, Axel Grothey, Anthony F Shields, Mohamed E Salem, John L Marshall, W Michael Korn, Dominik Wolf, Florian Kocher, Andreas Seeber,

Werner syndrome gene (WRN) contributes to DNA repair. In cancer, WRN mutations (WRN-mut) lead to genomic instability. Thus, WRN is a promising target in cancers with microsatellite instability (MSI). We assessed this study to investigate the molecular profile of WRN-mut in colorectal cancer (CRC). Tumor samples were analyzed using next-generation ... Read more >>

Cancers (Basel) (Cancers)
[2020, 12(5):]

Cited: 0 times

View full text PDF listing >>



Colorectal cancer care in the age of coronavirus: strategies to reduce risk and maintain benefit.

John L Marshall, Ronit I Yarden, Benjamin A Weinberg,

(Colorectal Cancer)
[2020, 0(0):]

Cited: 0 times

View full text PDF listing >>



Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma.

Matthew K Stein, Forrest W Williard, Joanne Xiu, Miriam W Tsao, Michael G Martin, Benjamin W Deschner, Paxton V Dickson, Evan S Glazer, Danny Yakoub, David Shibata, Axel F Grothey, Philip A Philip, Jimmy J Hwang, Anthony F Shields, John L Marshall, W Michael Korn, Heinz-Josef Lenz, Jeremiah L Deneve,

BACKGROUND AND OBJECTIVES:Peritoneal metastases (PM) from primary colorectal cancer (pCRC) are associated with poor outcomes; however, molecular differences are not well defined. METHODS:We compared unpaired tumor profiles of patients with pCRC and PM from Caris Life Sciences. Testing included next-generation sequencing of 592 genes, microsatellite instability (MSI) and tumor mutational ... Read more >>

J Surg Oncol (Journal of surgical oncology)
[2020, 121(8):1320-1328]

Cited: 0 times

View full text PDF listing >>



Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer.

Mohamed E Salem, Francesca Battaglin, Richard M Goldberg, Alberto Puccini, Anthony F Shields, David Arguello, W Michael Korn, John L Marshall, Axel Grothey, Heinz-Josef Lenz,

BACKGROUND:The incidence of colorectal cancer (CRC), particularly left-sided tumors (LT), in adolescents and young adults (AYA) is rising. Epigenetic events appear to play an important role in tumorigenesis and cancer progression, especially in younger patients. We compared molecular features of LT to right-sided tumors (RT) in AYA. MATERIALS AND METHODS:A ... Read more >>

Oncologist (The oncologist)
[2020, 25(5):404-413]

Cited: 0 times

View full text PDF listing >>



Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.

Bhavana Pendurthi Singh, John L Marshall, Aiwu Ruth He,

As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstream, their side-effect profile raises new challenges. In 2011, the Food and Drug Administration approved the first checkpoint inhibitor for the treatment of advanced melanoma, and since then, checkpoint inhibitors have demonstrated efficacy in many other tumor ... Read more >>

Oncologist (The oncologist)
[2020, 25(3):197-202]

Cited: 0 times

View full text PDF listing >>



Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets.

Benjamin A Weinberg, Joanne Xiu, Michael R Lindberg, Anthony F Shields, Jimmy J Hwang, Kelsey Poorman, Mohamed E Salem, Michael J Pishvaian, Randall F Holcombe, John L Marshall, Michael A Morse,

Background:Biliary tract cancers (BTCs) are a heterogeneous group of aggressive, rare malignancies with limited standard chemotherapeutic options for advanced disease. Recent studies have demonstrated potential novel biliary cancer targets and a possible role for immunotherapy in the treatment of patients with this disease. Intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and ... Read more >>

J Gastrointest Oncol (Journal of gastrointestinal oncology)
[2019, 10(4):652-662]

Cited: 0 times

View full text PDF listing >>



A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Anteneh A Tesfaye, Hongkun Wang, Marion L Hartley, Aiwu Ruth He, Louis Weiner, Nina Gabelia, Lana Kapanadze, Muhammad Shezad, Jonathan R Brody, John L Marshall, Michael J Pishvaian,

Purpose: Despite the wide adoption of tumor molecular profiling, there is a dearth of evidence linking molecular biomarkers for treatment selection to prediction of treatment outcomes in patients with metastatic pancreatic cancer. We initiated a pilot study to test the feasibility of designing a larger phase II trial of molecularly ... Read more >>

J Pancreat Cancer (Journal of pancreatic cancer)
[2019, 5(1):12-21]

Cited: 0 times

View full text PDF listing >>



The current state of molecular testing in the treatment of patients with solid tumors, 2019.

Wafik S El-Deiry, Richard M Goldberg, Heinz-Josef Lenz, Anthony F Shields, Geoffrey T Gibney, Antoinette R Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I Heath, Surasak Phuphanich, Edward Kim, Andrew J Brenner, John L Marshall,

The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor ... Read more >>

CA Cancer J Clin (CA: a cancer journal for clinicians)
[2019, 69(4):305-343]

Cited: 2 times

View full text PDF listing >>



Sequencing beyond the second-line setting in metastatic colorectal cancer.

Axel Grothey, John L Marshall, Tanios Bekaii-Saab,

The standard treatment for patients with metastatic colorectal cancer (mCRC) in the first- and second-line setting is generally chemotherapy, which can be augmented with vascular endothelial growth factor-targeted therapies and, for patients with KRAS wild-type status, epidermal growth factor receptor-targeted therapies. However, nearly all patients ultimately develop disease progression and ... Read more >>

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2019, 17 Suppl 7(3):1-19]

Cited: 0 times

View full text PDF listing >>



Options for patients with metastatic colorectal cancer who progress after second-line therapy.

John L Marshall,

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2019, 17 Suppl 7(3):2-4]

Cited: 0 times

View full text PDF listing >>



Biomarkers for immune therapy in gastrointestinal cancers.

Benjamin A Weinberg, Rumaisa Hameed, John L Marshall,

Immunotherapy with checkpoint blockade of pro-grammed death 1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) has substantially increased the number of anticancer agents in our arsenal. However, these therapies are not effective in all cancer types, benefitting only a subset of patients with susceptible, immunogenic cancers. This problem is especially ... Read more >>

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2019, 17(2):109-119]

Cited: 2 times

View full text PDF listing >>



Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Ryuma Tokunaga, Joanne Xiu, Curtis Johnston, Richard M Goldberg, Philip A Philip, Andreas Seeber, Madiha Naseem, Jae Ho Lo, Hiroyuki Arai, Francesca Battaglin, Alberto Puccini, Martin D Berger, Shivani Soni, Wu Zhang, Jimmy J Hwang, Anthony F Shields, John L Marshall, Hideo Baba, W Michael Korn, Heinz-Josef Lenz,

PURPOSE:The natural history and prognosis of appendiceal adenocarcinomas differ from those of adenocarcinomas arising in other large bowel sites. We aimed to compare the molecular profiles exhibited by appendiceal adenocarcinomas and colorectal cancers, or between the histopathologic subtypes of appendiceal adenocarcinoma. EXPERIMENTAL DESIGN:A total of 183 samples from appendiceal adenocarcinoma ... Read more >>

Clin. Cancer Res. (Clinical cancer research : an official journal of the American Association for Cancer Research)
[2019, 25(10):3096-3103]

Cited: 0 times

View full text PDF listing >>



Sequencing beyond the second-line setting in metastatic colorectal cancer: further observations.

Axel Grothey, John L Marshall, Tanios Bekaii-Saab,

Clin Adv Hematol Oncol (Clinical advances in hematology & oncology : H&O)
[2019, 17 Suppl 7(3):16-18]

Cited: 0 times

View full text PDF listing >>



Colon Cancer in Young Adults: Trends and Their Implications.

Benjamin A Weinberg, John L Marshall,

PURPOSE OF REVIEW:The recent rise of young individuals under age 50 with colorectal cancer (CRC) is a startling trend in need of greater focus and research. The etiology of young-onset CRC is unexplained as efforts to blame obesity or diabetes as causative factors are simplistic and inadequate. RECENT FINDINGS:We describe ... Read more >>

Curr Oncol Rep (Current oncology reports)
[2019, 21(1):3]

Cited: 4 times

View full text PDF listing >>



Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.

Sunnie Kim, James E Signorovitch, Hongbo Yang, Oscar Patterson-Lomba, Cheryl Q Xiang, Brian Ung, Monika Parisi, John L Marshall,

INTRODUCTION:nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited. METHODS:This retrospective cohort study compared the efficacy and safety of 1L nab-P + G versus FFX, overall and under specific treatment ... Read more >>

Adv Ther (Advances in therapy)
[2018, 35(10):1564-1577]

Cited: 6 times

View full text PDF listing >>



Reprint of: Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer.

Eveline E Vietsch, Garrett T Graham, Justine N McCutcheon, Aamir Javaid, Giuseppe Giaccone, John L Marshall, Anton Wellstein,

Cancer is a heterogeneous disease harboring diverse subclonal populations that can be discriminated by their DNA mutations. Environmental pressure selects subclones that ultimately drive disease progression and tumor relapse. Circulating cell-free DNA (ccfDNA) can be used to approximate the mutational makeup of cancer lesions and can serve as a marker ... Read more >>

Cancer Genet (Cancer genetics)
[2018, 228-229:131-142]

Cited: 1 time

View full text PDF listing >>



Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

Mohamed E Salem, Jun Yin, Benjamin A Weinberg, Lindsay A Renfro, Levi D Pederson, Timothy S Maughan, Richard A Adams, Eric Van Cutsem, Alfredo Falcone, Niall C Tebbutt, Matthew T Seymour, Eduardo Díaz-Rubio, Enrique Aranda, Carsten Bokemeyer, Volker Heinemann, Harpreet Wasan, Aimery de Gramont, Axel Grothey, Qian Shi, Daniel J Sargent, John L Marshall,

PURPOSE:Patients with left-sided colon tumours have better survival and respond differently to biologics compared with patients with right-sided tumours. Left-sided colon tumours and rectal cancers are often grouped together. Herein, we examined the clinicopathological differences and outcomes between left-sided colon and rectal cancers. PATIENTS AND METHODS:Data from 2879 metastatic colorectal ... Read more >>

Eur. J. Cancer (European journal of cancer (Oxford, England : 1990))
[2018, 103:205-213]

Cited: 0 times

View full text PDF listing >>



Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types.

Arielle L Heeke, Michael J Pishvaian, Filipa Lynce, Joanne Xiu, Jonathan R Brody, Wang-Juh Chen, Tabari M Baker, John L Marshall, Claudine Isaacs,

Purpose:The prevalence of homologous recombination DNA damage repair (HR-DDR) deficiencies among all tumor lineages is not well characterized. Therapy directed toward homologous recombination DDR deficiency (HRD) is now approved in ovarian and breast cancer, and there may be additional opportunities for benefit for patients with other cancers. Comprehensive evaluations for ... Read more >>

JCO Precis Oncol (JCO precision oncology)
[2018, 2018:]

Cited: 8 times

View full text PDF listing >>



Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

Alberto Puccini, Heinz-Josef Lenz, John L Marshall, David Arguello, Derek Raghavan, W Michael Korn, Benjamin A Weinberg, Kelsey Poorman, Arielle L Heeke, Philip A Philip, Anthony F Shields, Richard M Goldberg, Mohamed E Salem,

BACKGROUND:The incidence of colorectal cancer (CRC) in younger patients is rising, mostly due to tumors in the descending colon and rectum. Therefore, we aimed to explore the molecular differences of left-sided CRC between younger (≤45 years) and older patients (≥65). SUBJECTS, MATERIALS, AND METHODS:In total, 1,126 CRC tumor samples from ... Read more >>

Oncologist (The oncologist)
[2019, 24(3):319-326]

Cited: 3 times

View full text PDF listing >>



Underuse of exon mutational analysis for gastrointestinal stromal tumors.

Alex J Bartholomew, Hayden Dohnalek, Petra A Prins, Suzanne C O'Neill, Humair S Quadri, John L Marshall, Nadim G Haddad, Waddah B Al-Refaie,

BACKGROUND:Tyrosine kinase inhibitors (TKI) have become the guideline-recommended therapy for high-risk resected and advanced gastrointestinal stromal tumors (GISTs). Exon mutational analysis (EMA) is used to inform pretherapy response to TKI and may predict overall prognosis. Despite these benefits, EMA remains underused, and its impact on TKI therapy decision-making remains unexplored. ... Read more >>

J. Surg. Res. (The Journal of surgical research)
[2018, 231:43-48]

Cited: 0 times

View full text PDF listing >>



Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

Mohamed E Salem, Alberto Puccini, Joanne Xiu, Derek Raghavan, Heinz-Josef Lenz, W Michael Korn, Anthony F Shields, Philip A Philip, John L Marshall, Richard M Goldberg,

BACKGROUND:Gastroesophageal cancers are often grouped together even though cancers that originate in the esophagus often exhibit different histological features, geographical distribution, risk factors, and clinical characteristics than those originating in the stomach. Herein, we aimed to compare the molecular characteristics of three different gastroesophageal cancer types: esophageal squamous cell carcinoma ... Read more >>

Oncologist (The oncologist)
[2018, 23(11):1319-1327]

Cited: 6 times

View full text PDF listing >>



Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Michael M Boyiadzis, John M Kirkwood, John L Marshall, Colin C Pritchard, Nilofer S Azad, James L Gulley,

The U.S. Food and Drug Administration (FDA) recently approved pembrolizumab, an anti- programmed cell death protein 1 cancer immunotherapeutic, for use in advanced solid tumors in patients with the microsatellite-high/DNA mismatch repair-deficient biomarker. This is the first example of a tissue-agnostic FDA approval of a treatment based on a patient's ... Read more >>

J Immunother Cancer (Journal for immunotherapy of cancer)
[2018, 6(1):35]

Cited: 17 times

View full text PDF listing >>



Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.

Benjamin A Weinberg, Joanne Xiu, Jimmy J Hwang, Anthony F Shields, Mohamed E Salem, John L Marshall,

PURPOSE:The treatment of patients with advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinomas has been transformed by the U.S. Food and Drug Administration approval of pembrolizumab. Tumor and adjacent tissue must stain positively for the programmed cell death ligand 1 (PD-L1) protein by companion diagnostic testing. However, some patients with PD-L1-negative ... Read more >>

Oncologist (The oncologist)
[2018, 23(10):1171-1177]

Cited: 2 times

View full text PDF listing >>



Advertisement

Disclaimer
1.465 s